Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Lineage Cell Therapeutics to a loss of $0.03 per share from a previous loss estimate of $0.01, while maintaining a “Buy” rating.
• Lineage’s latest quarterly results matched expectations with a $0.03-per-share loss, but revenue of $1.07 million fell short of the $1.84 million analyst consensus.
• Analyst sentiment remains positive, with four Buy ratings and a consensus price target of $6.25; institutional investors and hedge funds own 62.47% of the company.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Lineage Cell Therapeutics in a research note issued on Friday, August 7th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.03) per share for the quarter, down from their previous estimate of ($0.01). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.07) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics' Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.08) EPS and FY2027 earnings at ($0.09) EPS.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.84 million. Lineage Cell Therapeutics had a negative return on equity of 82.83% and a negative net margin of 246.58%.

A number of other equities analysts have also recently issued reports on LCTX. Canaccord Genuity Group assumed coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They issued a "buy" rating and a $9.00 price objective for the company. D. Boral Capital reissued a "buy" rating and issued a $3.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, May 4th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $6.25.

Lineage Cell Therapeutics Stock Up 2.7%

LCTX opened at $1.13 on Tuesday. The stock's 50 day moving average price is $1.20 and its two-hundred day moving average price is $1.44. The firm has a market capitalization of $285.79 million, a P/E ratio of -5.95 and a beta of 1.53. Lineage Cell Therapeutics has a 12-month low of $0.97 and a 12-month high of $2.09.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of institutional investors have recently added to or reduced their stakes in LCTX. Royal Bank of Canada raised its position in shares of Lineage Cell Therapeutics by 1,578.9% in the first quarter. Royal Bank of Canada now owns 528,656 shares of the company's stock valued at $237,000 after purchasing an additional 497,168 shares during the period. Rhumbline Advisers grew its stake in Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company's stock valued at $91,000 after buying an additional 18,092 shares during the last quarter. XTX Topco Ltd grew its stake in Lineage Cell Therapeutics by 117.8% in the 2nd quarter. XTX Topco Ltd now owns 94,054 shares of the company's stock valued at $85,000 after buying an additional 50,876 shares during the last quarter. Jump Financial LLC bought a new position in Lineage Cell Therapeutics in the 2nd quarter valued at about $28,000. Finally, WINTON GROUP Ltd bought a new position in Lineage Cell Therapeutics in the 2nd quarter valued at about $69,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source